Key market Insights ? More than 100 next generation RNA therapeutics and vaccines are being developed to offer an advanced, low-dose form of treatment, targeting a wide range of therapeutic indications ? 75% of the next generation therapies are still in discovery and preclinical stages, primarily targeting infectious diseases; industry players are actively engaged in advancing their next generation drug portfolio ? Over 35 next generation RNA technologies are being developed / offered by companies for the research, discovery, design, development, manufacturing and delivery of novel RNA therapies and vaccines ? Around 55% of the technologies are used in the development of circular RNA-based therapeutics and vaccines; majority of such technologies facilitate targeted therapy delivery at a specific site within the cell ? Majority of the trials focused on RNA therapeutics and vaccines were registered in 2022; more than 70% of these studies have either been completed / are currently recruiting patients across different locations ? Close to 1,170 patents have been filed / granted for next generation RNA therapeutics and vaccines, by industry and non-industry players, to protect intellectual property generated within this field ? Around 70% of the deals inked in this market were focused on clinical research of saRNA therapeutics / vaccines; of these, more than 60% partnerships were inked for the treatment of infectious diseases ? Several investors, having realized the opportunity within this domain, have invested close to USD 2.9 Billion across various funding rounds in the past four years ? The rising interest of big pharma players is reflected by the increase in the number of next generation RNA therapeutics / vaccines-focused initiatives, including partnerships and funding, undertaken in recent years ? The market opportunity associated with next generation RNA therapeutics and vaccines is expected to witness an annualized growth rate of 50% over the coming 12 years ? The estimated market opportunity is expected to be well distributed across various routes of administration, geographical regions and leading players Table of Contents 1. PREFACE 1.1. RNA Therapeutics and RNA Vaccines Market Overview 1.2. Key Market Insights 1.3. Scope of the Report 1.4. Research Methodology 1.5. Frequently Asked Questions 1.6. Chapter Outlines 2. RESEARCH METHODOLOGY 2.1. Chapter Overview 2.2. Research Assumptions 2.3. Project Methodology 2.4. Forecast Methodology 2.5. Robust Quality Control 2.6. Key Market Segmentations 2.7. Key Considerations 3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS 3.1. Chapter Overview 3.2. Market Dynamics 4. EXECUTIVE SUMMARY 5. INTRODUCTION 5.1. An Overview of Next Generation RNA Therapeutics and Vaccines 5.2. Key Contributors in the Evolution of Next Generation RNA Therapeutics and Vaccines 5.3. Types of Next Generation RNA Molecules 5.4. Key Aspects of Next Generation RNA Molecules 5.5. Key Challenges Associated with Traditional RNA Modalities 5.6. Advantages of Using Next Generation RNA Modalities 6. MARKET LANDSCAPE 6.1. RNA Therapeutics and RNA Vaccines: Overall Therapies Landscape 6.1.1. Analysis by Type of Modality 6.1.2. Analysis by Type of Molecule 6.1.3. Analysis by Delivery Vehicle 6.1.4. Analysis by Phase of Development 6.1.5. Analysis by Therapeutic Area 6.1.6. Most Active Players: Analysis by Number of Therapies 6.2 RNA Therapeutics and RNA Vaccines: Clinical Stage Therapies Landscape 6.2.1. Analysis by Phase of Development 6.2.2. Analysis by Route of Administration 6.2.3. Analysis by Therapeutic Area 6.3. RNA Therapeutics and RNA Vaccines: Therapy Developers Landscape 6.3.1. Analysis by Year of Establishment 6.3.2. Analysis by Company Size 6.3.3. Analysis by Location of Headquarters 6.4. RNA Therapeutics and RNA Vaccines: Circular RNA Therapies Landscape 6.4.1. Analysis by Phase of Development 6.4.2. Analysis by Therapeutic Area 6.4.3. Most Active Players: Analysis by Number of Therapies 6.5. RNA Therapeutics and RNA Vaccines: Self-amplifying RNA Therapies Landscape 6.5.1. Analysis by Phase of Development 6.5.2. Analysis by Therapeutic Area 6.5.3. Most Active Players: Analysis by Number of Therapies 7. TECHNOLOGY LANDSCAPE 7.1. RNA Therapeutics and RNA Vaccines: Next Generation RNA Technologies Landscape 7.1.1. Analysis by Class of Molecule 7.1.2. Analysis by Type of Molecule 7.1.3. Analysis by Capabilities of the Technology 7.1.4. Analysis by Therapeutic Area 7.1.5. Analysis by Highest Phase of Development 7.2. RNA Therapeutics and RNA Vaccines: Next Generation RNA Technology / Platform Developers Landscape 7.2.1. Analysis by Year of Establishment 7.2.2. Analysis by Company Size 7.2.3. Analysis by Location of Headquarters 7.2.4. Analysis by Operational Model 8. DRUG PROFILES 8.1. Gemcovac 8.1.1. Developer Overview 8.1.2. Drug Overview 8.1.3. Clinical Trial Information 8.1.4. Clinical Trial Endpoints 8.1.5. Clinical Trial Results 8.1.6. Estimated Sales 8.2. ATYR1923 8.3. ARCT-154 8.4. GRT-C901 8.5. VLPCOV-01 8.6. AVX901 8.7. MTL-CEBPA + Sorafenib 8.8. SLATE 9. CLINICAL TRIAL ANALYSIS 9.1. Analysis Methodology and Key Parameters 9.2. RNA Therapeutics and RNA Vaccines: Clinical Trial Analysis 9.2.1. Analysis by Trial Registration Year 9.2.2. Analysis by Trial Status 9.2.3. Analysis by Trial Registration Year and Trial Status 9.2.4. Analysis by Trial Phase 9.2.5. Analysis by Patients Enrolled 9.2.6. Analysis by Type of Sponsor 9.2.7. Analysis by Therapeutic Area 9.2.8. Analysis by Study Design 9.2.9. Leading Organizations: Analysis by Number of Trials 9.2.10. Analysis by Focus Area 9.2.11. Analysis by Geography 10. PATENT ANALYSIS 10.1. Analysis Methodology and Key Parameters 10.2. RNA Therapeutics and RNA Vaccines: Patent Analysis 10.2.1. Analysis by Type of Patent 10.2.2. Analysis by Patent Publication Year 10.2.3. Analysis by Patent Jurisdiction 10.2.3.1. Analysis by Patent Jurisdiction: North American Scenario 10.2.3.2. Analysis by Patent Jurisdiction: European Scenario 10.2.3.3. Analysis by Patent Jurisdiction: Asia-Pacific Scenario 10.2.4. Analysis by CPC Symbols 10.2.5. World Cloud Analysis: Emerging Focus Areas 10.2.6. Analysis by Patent Age 10.2.7. Leading Industry Players: Analysis by Number of Patents 10.2.8. Leading Non-Industry Players: Analysis by Number of Patents 10.3. RNA Therapeutics and RNA Vaccines: Patent Benchmarking Analysis 10.4. RNA Therapeutics and RNA Vaccines: Patent Valuation Analysis 11. PARTNERSHIPS AND COLLABORATIONS 11.1. Partnership Models 11.2. RNA Therapeutics and RNA Vaccines: Partnerships and Collaborations 11.2.1. Analysis by Year of Partnership 11.2.2. Analysis by Type of Partnership 11.2.3. Analysis by Year and Type of Partnership 11.2.4. Analysis by Year and Type of Molecule 11.2.5. Analysis by Focus of Partnership 11.2.6. Analysis by Purpose of Partnership 11.2.7. Analysis by Therapeutic Area 11.2.8. Most Active Players: Analysis by Number of Partnerships 11.2.9. Analysis by Geography 11.2.9.1. Local and International Agreements 11.2.9.2. Intracontinental and Intercontinental Agreements 12. FUNDING AND INVESTMENT ANALYSIS 12.1. Types of Funding 12.2. RNA Therapeutics and RNA Vaccines: Funding and Investment Analysis 12.3. Analysis by Year of Funding 12.4. Analysis by Type of Funding 12.5. Analysis by Type of Molecule 12.6. Analysis of Amount Invested by Year of Funding 12.7. Analysis of Amount Invested by Type of Funding 12.8. Analysis by Geography 12.9. Analysis by Year and Type of Funding 12.10. Analysis by Purpose of Funding 12.11. Analysis by Stage of Development 12.12. Analysis by Therapeutic Area 12.13. Most Active Players: Analysis by Number of Funding Instances 12.14. Most Active Players: Analysis by Amount Invested 12.15. Leading Investors: Analysis by Number of Funding Instances 13. BIG PHARMA INITIATIVES 13.1. RNA Therapeutics and RNA Vaccines: Big Pharma Initiatives 13.1.1. Analysis by Number of Initiatives 13.1.2. Analysis by Year of Initiative 13.1.3. Analysis by Type of Initiative 13.1.3.1. Analysis by Type of Partnership 13.1.3.2. Analysis by Type of Funding 13.1.4. Analysis by Purpose of Initiative 13.1.5. Analysis by Year and Number of Initiatives 13.1.6. Analysis by Focus of Initiative 13.1.7. Analysis by Location of Headquarters of Big Pharma Players 14. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, 2023-2035 14.1. Key Assumptions and Methodology 14.2. Overall RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035) 14.2.1. Scenario Analysis 14.3. Key Market Segmentations 14.4. Dynamic Dashboard 15. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MODALITY 15.1. Therapeutics: Forecasted Estimates (2023-2035) 15.2. Vaccines: Forecasted Estimates (2023-2035) 15.3. Data Triangulation and Validation 16. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MOLECULE 16.1. repRNA: Forecasted Estimates (2023-2035) 16.2. saRNA: Forecasted Estimates (2023-2035) 16.3. sacRNA: Forecasted Estimates (2023-2035) 16.4. sa-mRNA: Forecasted Estimates (2023-2035) 16.5. tRNA: Forecasted Estimates (2023-2035) 16.6. Data Triangulation and Validation 17. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY THERAPEUTIC AREA 17.1. Infectious Diseases: Forecasted Estimates (2023-2035) 17.2. Oncological Disorders: Forecasted Estimates (2023-2035) 17.3. Pulmonary Disorders: Forecasted Estimates (2023-2035) 17.4. Data Triangulation and Validation 18. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY ROUTE OF ADMINISTRATION 18.1. Intradermal Therapeutics and Vaccines: Forecasted Estimates (2023-2035) 18.2. Intramuscular Therapeutics and Vaccines: Forecasted Estimates (2023-2035) 18.3. Intravenous Therapeutics and Vaccines: Forecasted Estimates (2023-2035) 18.4. Data Triangulation and Validation 19. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY KEY GEOGRAPHICAL REGIONS 19.1. North America: Forecasted Estimates (2023-2035) 19.1.1. US: Forecasted Estimates (2023-2035) 19.2. Europe: Forecasted Estimates (2023-2035) 19.2.1. France: Forecasted Estimates (2023-2035) 19.2.2. Italy: Forecasted Estimates (2023-2035) 19.2.3. Spain: Forecasted Estimates (2023-2035) 19.2.4. UK: Forecasted Estimates (2023-2035) 19.2.5. The Netherlands: Forecasted Estimates (2023-2035) 19.3. Asia-Pacific: Forecasted Estimates (2023-2035) 19.3.1. India: Forecasted Estimates (2023-2035) 19.3.2. Japan: Forecasted Estimates (2023-2035) 19.3.3. Singapore: Forecasted Estimates (2023-2035) 19.4. Data Triangulation and Validation 20. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY LEADING PLAYERS 20.1. Company A 20.2. Company B 20.3. Company C 20.4. Company D 20.5. Company E 21. CONCLUSION 22. APPENDIX 1: TABULATED DATA 23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS To view more details on this report, click on the link https://www.rootsanalysis.com/reports/rna-therapeutics-market.html News article Buffer Preparation Market Learn from experts: do you know about these emerging industry trends? Novel Antibody Therapies: Current Scenario and Future Potential Transforming Biomanufacturing: Potential of Cell Free Systems About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com